• Propanc Biopharma reported preclinical results showing PRP reduced pancreatic cancer cell growth and invasiveness, including in chemotherapy-resistant cells.
• Combining PRP with galunisertib enhanced selected effects but increased suppression of normal-associated fibroblasts, reducing the treatment’s apparent selectivity.
• PRP alone showed greater selectivity for cancer-associated fibroblasts, supporting further investigation of its effects on the tumor microenvironment.
• An Australian patent application covers the combination approach; further validation in more complex models is planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020830PRIMZONEFULLFEED9867851) on November 02, 2026, and is solely responsible for the information contained therein.